Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Prostaatkanker: verbetering chirurgische uitkomsten sinds invoering volumenorm
mei 2025 | Chirurgie, Uro-oncologie